AOD-9604 Compassionate Use: Expanded Access vs. Commercial Offers
What expanded access is designed to do
FDA describes expanded access as a potential treatment pathway for a serious or immediately life-threatening condition when satisfactory alternatives are unavailable and enrollment in a clinical trial is not possible. The potential benefit must justify the risks, and access must not interfere with the product's clinical development. [1]
Those criteria describe a specific medical and regulatory assessment. They do not establish that every investigational compound has an available program or that a person qualifies simply because conventional treatment has been disappointing.
Where AOD-9604 fits into the question
AOD-9604 is a growth hormone fragment investigated in metabolic research. FDA advisory materials discuss its development history and the evidence relevant to proposed compounding uses. A review of that evidence is different from approval of a drug or authorization of a particular expanded-access program. [2]
The route also matters. Findings from an oral preparation cannot automatically establish an injectable product's exposure, effectiveness, or safety. A claim that a peptide is “studied for weight loss” leaves those product-specific questions unanswered.
Three pathways that should not be conflated
| Term | What it describes |
|---|---|
| Clinical trial | A research protocol designed to answer a scientific question |
| Expanded access | Potential treatment use of an investigational product under specific criteria outside a trial |
| Compounding | Preparation of a drug under a separate framework with ingredient and other requirements |
A patient-specific prescription is not an expanded-access authorization. Likewise, describing a pharmacy as a 503A facility does not establish that AOD-9604 qualifies for ordinary compounding. FDA explains that bulk ingredients must meet the applicable conditions; the facility label alone does not settle that question. [3]
What would support a real access claim?
An article claiming that a program exists should identify its sponsor, the investigational product, the condition involved, and the relevant program documentation. It should distinguish a general description of FDA's process from evidence that the specific product is actually available through that process.
A clinical-trial listing also needs careful interpretation. Registration does not itself establish effectiveness or create a commercial supply channel. The study's status and eligibility criteria concern that study, not general retail availability. [4]
Without those details, a monthly price or a proposed injection cycle is not an access explanation. It is a sales assumption presented in the language of research.
Does an advisory committee recommendation change access?
An advisory discussion can inform FDA's work, but it is not interchangeable with the final regulatory action. The relevant question is what decision has actually taken effect for the particular product or substance. A seller's summary of a meeting cannot substitute for that record.
Frequently asked questions
Is compassionate use the same as off-label prescribing?
No. Off-label prescribing concerns a use of an approved product outside its approved labeling. Expanded access concerns an investigational product under a different framework.
Does difficulty losing weight automatically qualify someone?
No. Expanded access has specific criteria and depends on the condition, alternatives, product, and individual assessment. It is not an automatic weight-management purchasing pathway.
